rs328
This is a stop gained variant in the LPL gene.
▶GWAS Catalog Trait Associations (136)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
GWAS Catalog Trait Associations (136)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
cholesterol in chylomicrons and extremely large VLDL measurement
cholesterol in large HDL measurement
cholesterol in large VLDL measurement
cholesterol in very large HDL measurement
cholesterol in very large VLDL measurement
cholesterol to total lipids in IDL percentage
cholesterol to total lipids in large HDL percentage
cholesterol to total lipids in medium HDL percentage
cholesterol to total lipids in medium VLDL percentage
cholesterol to total lipids in small VLDL percentage
▶ClinVar annotation
Cardiovascular phenotype; Hyperlipidemia, familial combined, LPL related (FCHL3); Hyperlipoproteinemia, type I; LPL-related disorder; not specified
View on ClinVar →▶Research that mentions this SNP (4)
▶Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor statusAssociationN=2,416Yu‐Ling Cen et al.(2013)· Molecular Carcinogenesis
A hospital-based case-control study in rural and urban India (1,204 cases; 1,212 controls) examined genetic and lifestyle risk factors for breast cancer. Four SNPs in FGFR2 (rs1219648, rs2420946, rs2981575, rs2981582) showed positive associations with breast cancer (ORs 1.32-1.47). Additional SNPs in obesity and metabolic genes (rs374748 in FBN2, rs2922763 in HNF4G, rs2116830 in KCNMA1, rs11121832 in MTHFR, rs16886165 in MAP3K1, rs11594610 in TCF7L2, rs2274459 in MLN) were associated with increased breast cancer risk. Waist-to-hip ratio ≥0.95 showed strong association (OR 3.78; 95% CI 2.92-4.89), and women living first 20 years in rural areas showed protective effect (OR 0.77).
▶Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoringReviewAlessandra Mangia et al.(2011)· Hepatology
This is a special issue of the Italian medical journal BeAdfiles (September 2012) dedicated to genetic conditioning in HIV and hepatitis virus infections. It reviews the major genetic polymorphisms that influence disease progression, treatment response, and drug toxicity in HIV and chronic hepatitis B and C infections, with particular emphasis on IL28B polymorphisms (rs809917 and others) predicting HCV treatment response to interferon-alpha and ribavirin therapy, and ITPA gene variants protecting against ribavirin-induced anemia. The issue also covers pharmacogenetic markers (CYP2B6, ABCB1, HLA-B*5701) and their clinical applications in antiretroviral therapy.
▶The association of common genetic variants in the APOA5, LPL and GCK genes with longitudinal changes in metabolic and cardiovascular traitsAssociationN=4,554Webster RJ et al.(2009)· Diabetologia
This longitudinal study of 4,554 participants from the Busselton Health Survey examined associations between four SNPs in APOA5, LPL, and GCK genes with glucose and lipid traits over time. Cross-sectional analyses confirmed that GCK rs1799884 was associated with fasting glucose (beta=0.01, p=0.003), APOA5 rs662799 and rs3135506 with triacylglycerol levels (p<0.0001), and LPL rs328 with reduced triacylglycerol and raised HDL-C. Longitudinal analyses (n=2,864) showed these genetic effects on lipid and glucose traits remain stable with age during adulthood.
▶Strategies and issues in the detection of pathway enrichment in genome-wide association studiesMethodsN=28,191Mun-Gwan Hong et al.(2009)· Human Genetics
This methodological study develops ProxyGeneLD software for converting genome-wide SNP association data to pathway-enriched gene sets and validates it on multiple large GWAS datasets. The authors demonstrate successful replication of pathway enrichment for plasma HDL levels (with CETP and ABCA1 in lipid metabolism pathways) across independent samples and identify positional gene clustering as a major source of spurious enrichment in pathway analyses of GWAS data.
About LPL
LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism. [provided by RefSeq, Jul 2008]
View all LPL variants →Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…